|Articles|April 15, 2002
Excludes most of Asia: Tacrolimus licensing deal links Sucampo, Fujisawa
Bethesda, MD-Sucampo Pharmaceuticals Inc. has won the exclusive right to license Fujisawa's tacrolimus for ophthalmic use in the United States, Europe, and much of the world.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
























